Testosterone replacement therapy is associated with an increased risk of urolithiasis
| Autor: | Adil H. Haider, Shehzad Basaria, Alexander P. Cole, Naeem Bhojani, Quoc-Dien Trinh, Tyler R. McClintock, Tracey Perez Koehlmoos, Marie-Therese I. Valovska, Wei Jiang, George E. Haleblian, Martin Kathrins, Nicollette K. Kwon |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Nephrology medicine.medical_specialty Hormone Replacement Therapy Urology Population 030232 urology & nephrology Risk Assessment Cohort Studies 03 medical and health sciences 0302 clinical medicine Urolithiasis Internal medicine medicine Humans Testosterone Testosterone replacement education education.field_of_study business.industry Hypogonadism Absolute risk reduction Testosterone (patch) Middle Aged Increased risk 030220 oncology & carcinogenesis Cohort Hormonal therapy business |
| Zdroj: | World Journal of Urology. 37:2737-2746 |
| ISSN: | 1433-8726 0724-4983 |
| Popis: | To determine whether TRT in men with hypogonadism is associated with an increased risk of urolithiasis. We conducted a population-based matched cohort study utilizing data sourced from the Military Health System Data Repository (a large military-based database that includes beneficiaries of the TRICARE program). This included men aged 40–64 years with no prior history of urolithiasis who received continuous TRT for a diagnosis of hypogonadism between 2006 and 2014. Eligible individuals were matched using both demographics and comorbidities to TRICARE enrollees who did not receive TRT. The primary outcome was 2-year absolute risk of a stone-related event, comparing men on TRT to non-TRT controls. There were 26,586 pairs in our cohort. Four hundred and eighty-two stone-related events were observed at 2 years in the non-TRT group versus 659 in the TRT group. Log-rank comparisons showed this to be a statistically significant difference in events between the two groups (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink